EP3042669A4 - Antitumor agent and antitumor effect enhancer - Google Patents

Antitumor agent and antitumor effect enhancer Download PDF

Info

Publication number: EP3042669A4
Authority: EP; European Patent Office
Prior art keywords: antitumor; effect enhancer; agent; antitumor agent; antitumor effect
Prior art date: 2013-09-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14842538.2A

Other languages

German (de)

French (fr)

Other versions

EP3042669A1 (en

EP3042669B1 (en

Inventor

Hiroyuki Okabe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Taiho Pharmaceutical Co Ltd

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-06

Filing date

2014-09-05

Publication date

2017-04-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3042669(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-05 Priority to HRP20230523TT priority Critical patent/HRP20230523T1/en

2014-09-05 Priority to SM20230167T priority patent/SMT202300167T1/en

2014-09-05 Priority to SI201432026T priority patent/SI3042669T1/en

2014-09-05 Priority to RS20230421A priority patent/RS64243B1/en

2014-09-05 Priority to EP23154967.6A priority patent/EP4201424A1/en

2014-09-05 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2016-07-13 Publication of EP3042669A1 publication Critical patent/EP3042669A1/en

2017-04-12 Publication of EP3042669A4 publication Critical patent/EP3042669A4/en

2023-03-08 Publication of EP3042669B1 publication Critical patent/EP3042669B1/en

2023-03-08 Application granted granted Critical

2024-01-24 Priority to HUS2400001C priority patent/HUS2400001I1/en

Status Active legal-status Critical Current

2034-09-05 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Endocrinology (AREA)

EP14842538.2A 2013-09-06 2014-09-05 Antitumor agent and antitumor effect enhancer Active EP3042669B1 (en)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
SM20230167T SMT202300167T1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer
SI201432026T SI3042669T1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer
RS20230421A RS64243B1 (en)	2013-09-06	2014-09-05	ANTI-TUMOR AGENT AND AGENT FOR IMPROVING ANTI-TUMOR EFFECT
EP23154967.6A EP4201424A1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer
HRP20230523TT HRP20230523T1 (en)	2013-09-06	2014-09-05	ANTI-TUMOR AGENT AND AGENT FOR IMPROVING ANTI-TUMOR EFFECT
HUS2400001C HUS2400001I1 (en)	2013-09-06	2024-01-24	Antitumor agent and antitumor effect enhancer

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2013184684		2013-09-06
PCT/JP2014/073436 WO2015034032A1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP23154967.6A Division EP4201424A1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer

Publications (3)

Publication Number	Publication Date
EP3042669A1 EP3042669A1 (en)	2016-07-13
EP3042669A4 true EP3042669A4 (en)	2017-04-12
EP3042669B1 EP3042669B1 (en)	2023-03-08

Family

ID=52628493

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP23154967.6A Pending EP4201424A1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer
EP14842538.2A Active EP3042669B1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP23154967.6A Pending EP4201424A1 (en)	2013-09-06	2014-09-05	Antitumor agent and antitumor effect enhancer

Country Status (24)

Country	Link
US (1)	US9943537B2 (en)
EP (2)	EP4201424A1 (en)
JP (2)	JP6425653B2 (en)
KR (1)	KR101993963B1 (en)
AU (1)	AU2014316030C1 (en)
CY (2)	CY1126037T1 (en)
DK (1)	DK3042669T3 (en)
ES (1)	ES2946472T3 (en)
FI (2)	FI3042669T3 (en)
FR (1)	FR24C1005I1 (en)
HR (1)	HRP20230523T1 (en)
HU (2)	HUE062034T2 (en)
LT (2)	LT3042669T (en)
NO (1)	NO2024005I1 (en)
PL (1)	PL3042669T3 (en)
PT (1)	PT3042669T (en)
RS (1)	RS64243B1 (en)
RU (1)	RU2682161C2 (en)
SI (1)	SI3042669T1 (en)
SM (1)	SMT202300167T1 (en)
TW (1)	TWI641385B (en)
UA (1)	UA121538C2 (en)
WO (1)	WO2015034032A1 (en)
ZA (1)	ZA201602258B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015034032A1 (en)	2013-09-06	2015-03-12	大鵬薬品工業株式会社	Antitumor agent and antitumor effect enhancer
AU2017205531B2 (en)	2016-01-08	2021-05-13	Les Laboratoires Servier	Anti-tumor agent containing immunomodulator and anti-tumor effect potentiator
EP3442534A1 (en) *	2016-04-13	2019-02-20	Boehringer Ingelheim International GmbH	Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
US20200148757A1 (en) *	2017-06-30	2020-05-14	Korea Advanced Institute Of Science And Technology	Conjugate of vegf-grab protein and drug, and use thereof
KR20220154986A (en)	2021-05-14	2022-11-22	윤상은	Portable Mask Strap Cutter
AR127893A1 (en) *	2021-12-10	2024-03-06	Servier Lab	CANCER THERAPY TARGETTING EGFR
WO2023140329A1 (en)	2022-01-21	2023-07-27	中外製薬株式会社	Medicine for treating or preventing cancer
JP7565132B2 (en)	2022-04-20	2024-10-10	中外製薬株式会社	Medicines for the treatment or prevention of cancer
WO2024177036A1 (en) *	2023-02-20	2024-08-29	大鵬薬品工業株式会社	Ftd-tpi combination preparation, pd-1 pathway antagonist, and combination use of vegf pathway antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0763529B1 (en)	1995-03-29	2003-07-23	Taiho Pharmaceutical Company Limited	Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US7312243B1 (en) *	2003-08-29	2007-12-25	Jay Pravda	Materials and methods for treatment of gastrointestinal disorders
US7799783B2 (en) *	2005-01-26	2010-09-21	Taiho Pharmaceutical Co., Ltd.	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
PT1849470T (en)	2005-01-26	2017-09-22	Taiho Pharmaceutical Co Ltd	Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
DK2979700T3 (en)	2013-03-27	2019-01-21	Taiho Pharmaceutical Co Ltd	ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE
NZ712584A (en) *	2013-03-27	2018-03-23	Taiho Pharmaceutical Co Ltd	Antitumor agent including irinotecan hydrochloride hydrate
WO2015034032A1 (en)	2013-09-06	2015-03-12	大鵬薬品工業株式会社	Antitumor agent and antitumor effect enhancer

2014
- 2014-09-05 WO PCT/JP2014/073436 patent/WO2015034032A1/en not_active Ceased
- 2014-09-05 US US14/916,878 patent/US9943537B2/en active Active
- 2014-09-05 RU RU2016112421A patent/RU2682161C2/en active
- 2014-09-05 DK DK14842538.2T patent/DK3042669T3/en active
- 2014-09-05 FI FIEP14842538.2T patent/FI3042669T3/en active
- 2014-09-05 SI SI201432026T patent/SI3042669T1/en unknown
- 2014-09-05 HR HRP20230523TT patent/HRP20230523T1/en unknown
- 2014-09-05 PL PL14842538.2T patent/PL3042669T3/en unknown
- 2014-09-05 EP EP23154967.6A patent/EP4201424A1/en active Pending
- 2014-09-05 PT PT148425382T patent/PT3042669T/en unknown
- 2014-09-05 TW TW103130882A patent/TWI641385B/en active
- 2014-09-05 LT LTEPPCT/JP2014/073436T patent/LT3042669T/en unknown
- 2014-09-05 SM SM20230167T patent/SMT202300167T1/en unknown
- 2014-09-05 AU AU2014316030A patent/AU2014316030C1/en active Active
- 2014-09-05 JP JP2015535524A patent/JP6425653B2/en active Active
- 2014-09-05 KR KR1020167005952A patent/KR101993963B1/en active Active
- 2014-09-05 EP EP14842538.2A patent/EP3042669B1/en active Active
- 2014-09-05 HU HUE14842538A patent/HUE062034T2/en unknown
- 2014-09-05 RS RS20230421A patent/RS64243B1/en unknown
- 2014-09-05 ES ES14842538T patent/ES2946472T3/en active Active
- 2014-09-05 UA UAA201603578A patent/UA121538C2/en unknown
2016
- 2016-04-05 ZA ZA2016/02258A patent/ZA201602258B/en unknown
2018
- 2018-01-15 JP JP2018004516A patent/JP6557744B2/en active Active
2023
- 2023-06-07 CY CY20231100271T patent/CY1126037T1/en unknown
2024
- 2024-01-24 HU HUS2400001C patent/HUS2400001I1/en unknown
- 2024-01-24 FR FR24C1005C patent/FR24C1005I1/en active Active
- 2024-01-24 CY CY2024001C patent/CY2024001I1/en unknown
- 2024-01-25 NO NO2024005C patent/NO2024005I1/en unknown
- 2024-01-25 FI FIC20240002C patent/FIC20240002I1/en unknown
- 2024-01-26 LT LTPA2024502C patent/LTPA2024502I1/lt unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O H TEMMINK ET AL: "Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells", BRITISH JOURNAL OF CANCER, vol. 96, no. 2, 29 January 2007 (2007-01-29), GB, pages 231 - 240, XP055229001, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6603549 *

Also Published As

Publication number	Publication date
WO2015034032A1 (en)	2015-03-12
JPWO2015034032A1 (en)	2017-03-02
PT3042669T (en)	2023-06-15
TWI641385B (en)	2018-11-21
JP6425653B2 (en)	2018-11-21
HUE062034T2 (en)	2023-09-28
ZA201602258B (en)	2017-09-27
KR20160050026A (en)	2016-05-10
CY2024001I2 (en)	2024-09-20
TW201536319A (en)	2015-10-01
RU2016112421A (en)	2017-10-11
ES2946472T3 (en)	2023-07-19
EP4201424A1 (en)	2023-06-28
DK3042669T3 (en)	2023-06-12
AU2014316030A1 (en)	2016-04-28
HUS2400001I1 (en)	2024-02-28
EP3042669A1 (en)	2016-07-13
CY1126037T1 (en)	2023-11-15
LTPA2024502I1 (en)	2024-03-12
US9943537B2 (en)	2018-04-17
EP3042669B1 (en)	2023-03-08
RU2016112421A3 (en)	2018-06-20
HRP20230523T1 (en)	2023-08-04
JP2018076369A (en)	2018-05-17
SI3042669T1 (en)	2023-07-31
RS64243B1 (en)	2023-06-30
PL3042669T3 (en)	2023-06-26
SMT202300167T1 (en)	2023-07-20
FI3042669T3 (en)	2023-05-25
AU2014316030C1 (en)	2024-08-15
FR24C1005I1 (en)	2024-04-19
KR101993963B1 (en)	2019-06-27
FIC20240002I1 (en)	2024-01-25
UA121538C2 (en)	2020-06-25
AU2014316030B2 (en)	2019-02-28
RU2682161C2 (en)	2019-03-15
CY2024001I1 (en)	2024-09-20
US20160193241A1 (en)	2016-07-07
JP6557744B2 (en)	2019-08-07
LT3042669T (en)	2023-06-26
NO2024005I1 (en)	2024-01-25

Publication	Publication Date	Title
EP3043784A4 (en)	2017-04-05	Aryl ethers and uses thereof
EP3053910A4 (en)	2017-05-17	Aniline derivatives and uses thereof
EP3030566A4 (en)	2017-03-22	Aza-pyridone compounds and uses thereof
ZA201505735B (en)	2016-05-25	Cancer drug and uses
EP2992097A4 (en)	2017-01-04	Compositions and methods
EP2951283A4 (en)	2017-01-25	Compositions and methods
EP3060561A4 (en)	2017-07-05	Strigolactone formulations and uses thereof
EP3011011A4 (en)	2017-05-31	Targeted integration
EP2968541A4 (en)	2017-02-08	Multivalent and monovalent multispecific complexes and their uses
EP3087059A4 (en)	2017-06-21	Indazoles and use thereof
HUS2400001I1 (en)	2024-02-28	Antitumor agent and antitumor effect enhancer
EP3041043A4 (en)	2017-04-05	Assembly and power-module substrate
EP3087950A4 (en)	2017-08-02	Artificial-blood-vessel connector and artificial-blood-vessel unit
EP3038458A4 (en)	2017-02-15	Sowing unit and uses thereof
EP3021042A4 (en)	2017-03-01	Headlamp unit and headlamp
EP2999482A4 (en)	2017-08-09	Prodrugs and drugs
EP3041045A4 (en)	2017-03-29	Assembly and power-module substrate
EP3017225A4 (en)	2017-02-22	Bracket and use
EP3041044A4 (en)	2017-03-01	Assembly and power-module substrate
EP3048108A4 (en)	2017-05-03	Thienopiperidine derivative and use thereof
EP3039511A4 (en)	2017-05-10	Attention-based rendering and fidelity
EP3030239A4 (en)	2017-03-08	Urea derivatives and uses thereof
AU2014361391A1 (en)	2016-04-28	Pyrazolyl pyrimidinamine compound and application thereof
EP3081565A4 (en)	2017-04-26	Pyrazolyl pyrimidinamine compound and application thereof
EP3042977A4 (en)	2017-05-24	Rolling component

Legal Events

Date	Code	Title	Description
2014-09-05	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20230523T Country of ref document: HR
2016-06-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-07-13	17P	Request for examination filed	Effective date: 20160322
2016-07-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-07-13	AX	Request for extension of the european patent	Extension state: BA ME
2017-04-12	A4	Supplementary search report drawn up and despatched	Effective date: 20170315
2017-04-12	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/7072 20060101ALI20170309BHEP Ipc: C07K 16/22 20060101ALI20170309BHEP Ipc: A61K 39/00 20060101ALI20170309BHEP Ipc: A61P 43/00 20060101ALI20170309BHEP Ipc: A61K 31/506 20060101ALI20170309BHEP Ipc: C07K 16/28 20060101ALI20170309BHEP Ipc: A61K 39/395 20060101AFI20170309BHEP Ipc: A61P 35/00 20060101ALI20170309BHEP Ipc: A61K 31/513 20060101ALI20170309BHEP
2019-10-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-11-27	17Q	First examination report despatched	Effective date: 20191029
2021-10-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2021-10-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2021-11-03	INTG	Intention to grant announced	Effective date: 20211008
2021-11-03	RIN1	Information on inventor provided before grant (corrected)	Inventor name: OKABE, HIROYUKI
2022-01-12	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2022-01-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-02-16	INTC	Intention to grant announced (deleted)
2022-03-13	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2022-03-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2022-04-13	INTG	Intention to grant announced	Effective date: 20220314
2022-07-22	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2022-07-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-08-31	INTC	Intention to grant announced (deleted)
2022-09-19	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2022-09-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2022-10-19	INTG	Intention to grant announced	Effective date: 20220920
2023-01-25	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-02-03	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-02-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-03-01	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: TAIHO PHARMACEUTICAL CO., LTD.
2023-03-08	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-03-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-03-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1552132 Country of ref document: AT Kind code of ref document: T Effective date: 20230315
2023-03-23	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014086431 Country of ref document: DE
2023-03-29	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-06-12	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20230607
2023-06-15	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 3042669 Country of ref document: PT Date of ref document: 20230615 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20230605
2023-06-21	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2023-06-27	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2023-07-10	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20230308
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230527
2023-07-17	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E023315 Country of ref document: EE Effective date: 20230530
2023-07-19	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2946472 Country of ref document: ES Kind code of ref document: T3 Effective date: 20230719
2023-07-20	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20230400813 Country of ref document: GR Effective date: 20230710
2023-07-26	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 41672 Country of ref document: SK
2023-08-04	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20230523 Country of ref document: HR
2023-09-15	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20230523 Country of ref document: HR Payment date: 20230809 Year of fee payment: 10
2023-09-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E062034 Country of ref document: HU
2023-11-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R026 Ref document number: 602014086431 Country of ref document: DE
2023-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230308
2023-12-01	PLBI	Opposition filed	Free format text: ORIGINAL CODE: 0009260
2023-12-15	PLBI	Opposition filed	Free format text: ORIGINAL CODE: 0009260
2023-12-19	PLAX	Notice of opposition and request to file observation + time limit sent	Free format text: ORIGINAL CODE: EPIDOSNOBS2
2024-01-03	26	Opposition filed	Opponent name: CAMULON LIMITED Effective date: 20231129
2024-01-17	26	Opposition filed	Opponent name: GENERICS (U.K.) LIMITED Effective date: 20231207
2024-01-24	REG	Reference to a national code	Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: COMBINAISON DE TRIFLURIDINE ET TIPIRACIL (LONSURF) OU L'UN DE SES SELS EN ASSOCIATION AU BEVACIZUMAB.; REGISTRATION NO/DATE: EU/1/16/1096 20230727 Spc suppl protection certif: 24C1005 Filing date: 20240124
2024-01-25	REG	Reference to a national code	Ref country code: FI Ref legal event code: SPCF Ref document number: C20240002 Country of ref document: FI Spc suppl protection certif: C20240002 Filing date: 20240125 Expiry date: 20340905
2024-01-31	REG	Reference to a national code	Ref country code: NL Ref legal event code: SPCF Free format text: PRODUCT NAME: COMBINATIE VAN TRIFLURIDINE EN TIPIRACILL OF EEN ZOUT DAARVAN MET BEVACIZUMAB; REGISTRATION NO/DATE: EU/1/16/1096 20230727 Spc suppl protection certif: 301258 Filing date: 20240124 Expiry date: 20340904 Extension date: 20380726
2024-02-05	REG	Reference to a national code	Ref country code: NO Ref legal event code: SPCF Free format text: PRODUCT NAME: COMBINATION OF TRIFLURIDINE AND TIPIRACIL OR A SALT THEREOF WITH BEVACIZUMAB; REG. NO/DATE: EU/1/16/1096 20160509 Spc suppl protection certif: 2024005 Filing date: 20240125
2024-02-12	REG	Reference to a national code	Ref country code: DK Ref legal event code: CTFF Free format text: PRODUCT NAME: KOMBINATION AF TRIFLURIDIN OG TIPIRACIL ELLER ET SALT DERAF MED BEVACIZUMAB; REG. NO/DATE: EU/1/16/1096 20230727 Spc suppl protection certif: CA 2024 00004 Filing date: 20240125 Expiry date: 20340905 Extension date: 20380727
2024-02-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R065 Ref document number: 602014086431 Country of ref document: DE Free format text: PRODUCT NAME: KOMBINATION VON TRIFLURIDIN UND TIPIRACIL ODER EINEM SALZ VON TIPIRACIL MIT BEVACIZUMAB; REGISTRATION NO/DATE: EU/1/16/1096 20230726 Spc suppl protection certif: 122024000006 Filing date: 20240126 Expiry date: 20340906 Ref country code: IE Ref legal event code: SPCF Free format text: PRODUCT NAME: LONSURF IN COMBINATION WITH BEVACIZUMAB; REGISTRATION NO/DATE: EU/1/16/1096 20230726 Spc suppl protection certif: 2024/001 Filing date: 20240124
2024-02-26	REG	Reference to a national code	Ref country code: BE Ref legal event code: SPCF Free format text: PRODUCT NAME: LONSURF-TRIFLURIDINE/TIPIRACIL; AUTHORISATION NUMBER AND DATE: (AANPASSING VAN) EU/1/16/1096 20230726 Spc suppl protection certif: 2024C/503 Filing date: 20240125 Expiry date: 20340905 Extension date: 20380726
2024-02-27	REG	Reference to a national code	Ref country code: SE Ref legal event code: SPCF Free format text: PRODUCT NAME: COMBINATION OF TRIFLURIDINE AND TIPIRACIL OR A SALT THEREOF WITH BEVACIZUMAB; REG. NO/DATE: EU/1/16/1096 20230727 Spc suppl protection certif: 2490001-1
2024-02-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AA1S Ref document number: E062034 Country of ref document: HU Spc suppl protection certif: S2400001 Filing date: 20240124 Ref country code: GB Ref legal event code: CTFF Free format text: PRODUCT NAME: COMBINATION OF TRIFLURIDINE AND TIPIRACIL OR A SALT THEREOF WITH BEVACIZUMAB; REGISTERED: UK EU/1/16/1096(FOR NI) 20230727 Spc suppl protection certif: SPC/GB24/003 Filing date: 20240125
2024-03-11	REG	Reference to a national code	Ref country code: LU Ref legal event code: SPCF Free format text: PRODUCT NAME: COMBINAISON DE TRIFLURIDINE ET DE TIPIRACIL, OU D'UN SEL DE TIPIRACIL, AVEC DU BEVACIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20230727 Spc suppl protection certif: LUC00328 Filing date: 20240124 Expiry date: 20340905 Extension date: 20380727
2024-03-12	REG	Reference to a national code	Ref country code: LT Ref legal event code: SPCF Free format text: PRODUCT NAME: TRIFLURIDINO IR TIPIRACILO ARBA JU DRUSKU DERINYS SU BEVACIZUMABU; REGISTRATION NO/DATE: EU/1/16/1096 20230726 Spc suppl protection certif: PA2024502 Filing date: 20240126 Expiry date: 20340905
2024-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: SPCF Ref document number: 1552132 Country of ref document: AT Kind code of ref document: T Free format text: PRODUCT NAME: KOMBINATION VON TRIFLURIDIN UND TIPIRACIL ODER EIN SALZ DAVON MIT BEVACIZUMAB; REGISTRATION NO/DATE: EU/1/16/1096 (MITTEILUNG) 20230727 Spc suppl protection certif: 1/2024 Filing date: 20240125 Effective date: 20240315 Ref country code: EE Ref legal event code: AA1Y Ref document number: E023315 Country of ref document: EE Free format text: PRODUCT NAME: TRIFLURIDIIN / TIPIRATSIIL;REG NO/DATE: EU/1/16/1096 27.07.2023 Spc suppl protection certif: C20240001 Filing date: 20240125
2024-04-20	PLBB	Reply of patent proprietor to notice(s) of opposition received	Free format text: ORIGINAL CODE: EPIDOSNOBS3
2024-04-23	REG	Reference to a national code	Ref country code: ES Ref legal event code: SPCF Free format text: PRODUCT NAME: COMBINACION DE TRIFLURIDINA Y TIPIRACILO O UNA SAL DEL MISMO CON BEVAXIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1096; DATE OF AUTHORISATION: 20230726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1096; DATE OF FIRST AUTHORISATION IN EEA: 20230726 Spc suppl protection certif: C202430003 Effective date: 20240125
2024-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230308
2024-06-28	PGRI	Patent reinstated in contracting state [announced from national office to epo]	Ref country code: AL Effective date: 20230524
2024-07-26	PLAB	Opposition data, opponent's data or that of the opponent's representative modified	Free format text: ORIGINAL CODE: 0009299OPPO
2024-08-28	R26	Opposition filed (corrected)	Opponent name: CAMULON LIMITED Effective date: 20231129
2024-08-29	REG	Reference to a national code	Ref country code: BE Ref legal event code: SPCT Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME Spc suppl protection certif: 2024C/503 Effective date: 20240313
2024-09-04	REG	Reference to a national code	Ref country code: NL Ref legal event code: SPCD Free format text: PRODUCT NAME: COMBINATIE VAN TRIFLURIDINE EN TIPIRACIL OF EEN ZOUT DAARVAN MET BEVACIZUMAB; REGISTRATION NO/DATE: EU/1/16/1096 20230727 Spc suppl protection certif: 301258 Filing date: 20240124 Expiry date: 20340904 Extension date: 20380726 Effective date: 20240829
2024-09-27	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20230523 Country of ref document: HR Payment date: 20240806 Year of fee payment: 11
2024-10-16	REG	Reference to a national code	Ref country code: NL Ref legal event code: SPCO Spc suppl protection certif: 301258
2024-12-02	REG	Reference to a national code	Ref country code: BE Ref legal event code: SPCT Owner name: TAIHO PHARMACEUTICAL CO., LTD.; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME Spc suppl protection certif: 2024C/503 Effective date: 20240515 Ref country code: BE Ref legal event code: SPCT Owner name: TAIHO PHARMACEUTICAL CO., LTD.; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME Spc suppl protection certif: 2024C/503 Effective date: 20240822
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20241001 Year of fee payment: 11
2025-01-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20240814 Year of fee payment: 11
2025-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20241001 Year of fee payment: 11
2025-05-22	REG	Reference to a national code	Ref country code: ES Ref legal event code: SPCD Free format text: PRODUCT NAME: COMBINACION DE TRIFLURIDINA Y TIPIRACILO O UNA SAL DEL MISMO CON BEVAXIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1096; DATE OF AUTHORISATION: 20230726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1096; DATE OF FIRST AUTHORISATION IN EEA: 20230726 Spc suppl protection certif: C202430003
2025-07-02	REG	Reference to a national code	Ref country code: NL Ref legal event code: SPCU Free format text: DECISION: NEGATIVE Spc suppl protection certif: 301258 Filing date: 20240124 Expiry date: 20340904 Effective date: 20250630
2025-09-15	APAH	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNO
2025-09-15	APAW	Appeal reference deleted	Free format text: ORIGINAL CODE: EPIDOSDREFNO
2025-09-15	APBP	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2O
2025-09-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20250829 Year of fee payment: 12 Ref country code: NL Payment date: 20250814 Year of fee payment: 12
2025-09-26	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20230523 Country of ref document: HR Payment date: 20250808 Year of fee payment: 12
2025-10-01	REG	Reference to a national code	Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20251001
2025-10-06	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SM Payment date: 20250730 Year of fee payment: 12
2025-10-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20250912 Year of fee payment: 12 Ref country code: PT Payment date: 20250903 Year of fee payment: 12
2025-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LT Payment date: 20250804 Year of fee payment: 12 Ref country code: DK Payment date: 20250911 Year of fee payment: 12 Ref country code: DE Payment date: 20250730 Year of fee payment: 12
2025-10-13	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20250828 Year of fee payment: 12 Ref country code: NO Payment date: 20250909 Year of fee payment: 12 Ref country code: GR Payment date: 20250818 Year of fee payment: 12
2025-10-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20250825 Year of fee payment: 12 Ref country code: PL Payment date: 20250728 Year of fee payment: 12 Ref country code: TR Payment date: 20250903 Year of fee payment: 12
2025-10-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1552132 Country of ref document: AT Kind code of ref document: T Effective date: 20230308
2025-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BG Payment date: 20250815 Year of fee payment: 12 Ref country code: HU Payment date: 20250828 Year of fee payment: 12 Ref country code: BE Payment date: 20250818 Year of fee payment: 12 Ref country code: GB Payment date: 20250731 Year of fee payment: 12
2025-10-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HR Payment date: 20250808 Year of fee payment: 12
2025-10-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AL Payment date: 20250904 Year of fee payment: 12 Ref country code: FR Payment date: 20250808 Year of fee payment: 12 Ref country code: AT Payment date: 20250827 Year of fee payment: 12
2025-10-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MT Payment date: 20250917 Year of fee payment: 12 Ref country code: SE Payment date: 20250728 Year of fee payment: 12
2025-10-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RS Payment date: 20250815 Year of fee payment: 12 Ref country code: EE Payment date: 20250808 Year of fee payment: 12 Ref country code: IE Payment date: 20250812 Year of fee payment: 12 Ref country code: CZ Payment date: 20250821 Year of fee payment: 12
2025-10-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RO Payment date: 20250827 Year of fee payment: 12
2025-10-27	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SK Payment date: 20250812 Year of fee payment: 12
2025-10-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IS Payment date: 20250821 Year of fee payment: 12
2025-10-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LV Payment date: 20250805 Year of fee payment: 12
2025-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SI Payment date: 20250813 Year of fee payment: 12
2025-11-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MK Payment date: 20250806 Year of fee payment: 12
2025-11-15	APBQ	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3O